International (19 Offers)
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.78 g/mol
Brand: Dragon Pharma Peptide Line
Strength: 5 mg/vial
Unit: vial
Dragon Tesamorelin peptide is a synthetic analog of growth hormone-releasing hormone (GHRH) that is primarily utilized in medical contexts to address specific conditions related to lipodystrophy. By stimulating the pituitary gland, it promotes the secretion of growth hormone, which subsequently influences fat metabolism and body composition.
It is most commonly prescribed for individuals living with HIV-associated lipodystrophy to reduce excess abdominal fat, though it is not a weight-loss solution for general obesity. Due to its targeted action and potential side effects, including joint pain, increased blood sugar levels, and hypersensitivity reactions, the use of Tesamorelin peptide is approached cautiously and under strict medical supervision.
🛻 Free Shipping on orders over $1000
Molecular Formula: C225H348N48O68S2
Molecular Weight: 4813.03 g/mol
Brand: Dragon Pharma Peptide Line
Strength: 5 mg/vial
Unit: vial
Dragon Tirzepatide is a novel medication designed for the treatment of type 2 diabetes, and it is currently being investigated for potential applications in weight management. It is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual action harnesses the complementary effects of both incretin hormones to improve glycemic control and support metabolic health.
By enhancing insulin secretion in response to meals, reducing glucagon concentrations, and slowing gastric emptying, Tirzepatide peptide aids in stabilizing blood glucose levels. However, its use requires careful consideration of associated side effects such as nausea, diarrhea, and the potential increased risk of pancreatitis, emphasizing the need for healthcare providers to monitor patients closely during treatment.
🛻 Free Shipping on orders over $1000
Dragon Survodutide peptide is an investigational therapeutic agent under development that combines mechanisms targeting both appetite regulation and metabolic processes.
It is categorized as a dual GLP-1 and glucagon receptor agonist, functioning by influencing pathways involved in energy balance and glycemic control. This compound has been studied primarily for its potential applications in managing obesity and related metabolic disorders.
While its efficacy and safety are promising in preliminary trials, further rigorous clinical evaluation is essential to determine its long-term effects and appropriate use cases.
🛻 Free Shipping on orders over $1000
